ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstracts tagged "cyclophosphamide"

  • Abstract Number: 0433 • ACR Convergence 2021

    Use of 2-Mercaptoethane Sodium Sulfonate Prophylaxis in Cyclophosphamide-Treated Patients with ANCA-Associated Vasculitis: Results of an Electronic Survey

    Lukas Joos1, Solange Gonzalez Chiappe1, Thomas Neumann1 and Alfred Mahr2, 1Kantonsspital St.Gallen, St.Gallen, Switzerland, 2Kantonsspital St. Gallen, St.Gallen, Switzerland

    Background/Purpose: Co-prescribing mesna with CYC for AAV aims to prevent the potential urotoxic effects of CYC. We investigated current clinical practice related to prescribing mesna…
  • Abstract Number: 1460 • ACR Convergence 2021

    Lupus Nephritis Renal Responses in Relation to Treatment and Demographics: Observations from a Multi-racial/ethnic Cohort of 159 Patients in the NYU Lupus Registry

    Mayce Haj-Ali1, Kristina Deonaraine2, Alexis Engel3, Yingzhi Qian1, Amit Saxena4, Peter Izmirly2, Jill Buyon4 and H. Michael Belmont4, 1NYU Grossman School of Medicine, New York, NY, 2New York University School of Medicine, New York, NY, 3NYU Langone Health, New Yok, NY, 4NYU School of Medicine, New York, NY

    Background/Purpose: Lupus nephritis (LN) disproportionately affects racial and ethnic populations. Contreras reported African-American (AA) and Hispanic patients had worse outcomes as compared to patients of…
  • Abstract Number: 126 • 2020 Pediatric Rheumatology Symposium

    Cyclophosphamide as Rescue Therapy for Kawasaki Disease with Peripheral Vascular Disease: A Single Center Experience

    Ugo Awa1, Monica Bray 2 and Marietta De Guzman 3, 1Baylor College of Medicine, Houston, 2Section of Rheumatology, Department of Pediatrics, Baylor College of Medicine, Houston, 3Section of Rheumatology, Department of Pediatrics, Baylor College of Medicine, Houston, Texas

    Background/Purpose: Kawasaki Disease (KD) is the most common systemic vasculitis affecting children 5 years and younger. With coronary vessel involvement, KD is now the most…
  • Abstract Number: 141 • 2020 Pediatric Rheumatology Symposium

    Cyclophosphamide Use in Treatment of Refractory Kawasaki Disease: A Single Center Case Series of 10 Patients and Literature Review

    Olha Halyabar1, Mary Beth Son 2, Margaret Chang 3 and Robert Sundel 1, 1Children's Hospital/Boston Medical Center, Boston, 2Boston Children's Hospital, Boston, Massachusetts, 3Boston Children's Hospital, Boston

    Background/Purpose: Intravenous immunoglobulin (IVIG) effectively treats vasculitis of the coronary arteries in the large majority of Kawasaki Disease (KD) patients. However, approximately 25% of patients…
  • Abstract Number: 2632 • 2019 ACR/ARP Annual Meeting

    Changing Trends in the Management of ANCA-associated Vasculitis at an Academic Medical Center

    Sana Afroz1 and Najia Shakoor 2, 1RUMC, Chicago, IL, 2Rush University Medical Center, Chicago, IL

    Background/Purpose: For years, cyclophosphamide (CYC) has been the primary treatment for severe anca-associated vasculitides (AAV) and has significantly improved disease related mortality.  In addition, maintenance…
  • Abstract Number: 2633 • 2019 ACR/ARP Annual Meeting

    Efficacy of Remission Induction Regimens in Elderly Patients with ANCA-Associated Glomerulonephritis

    Audrey Hopkins1, Stanley Chu 2, Philip Seo 3, Eric Gapud 1, Brendan Antiochos 1, Shaker Eid 1, Jason Liebowitz 1 and Duvuru Geetha 1, 1Johns Hopkins Bayview Medical Center, Baltimore, 2Johns Hopkins University, Baltimore, 3Johns Hopkins Medicine, Baltimore, MD

    Background/Purpose: Induction regimens using either cyclophosphamide (CYC) or rituximab (RTX) have been shown to have similar efficacy and similar rates of adverse events in randomized…
  • Abstract Number: 812 • 2018 ACR/ARHP Annual Meeting

    Inflammatory Stays Inflammatory: A Subgroup of Systemic Sclerosis Characterized By High Morbidity and Inflammatory Resistance to Cyclophosphamide

    Aleksey Mitev1, Daria Feldmann1, Moritz Binder2, Kim Möller3, Anna-Maria Kanne1, Thomas Hügle4, Peter M. Villiger5, Reinhard Voll6, Stephanie Finzel1 and Florian Kollert7, 1Department of Rheumatology and Clinical Immunology, University Medical Center Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany, 2Department of Internal Medicine, Mayo Clinic, Rochester, MN, 3Rheumatology Research Group, Institute of Inflammation and Ageing, University of Birmingham, Birmingham, United Kingdom, 4Rheumatology, University Hospital Lausanne (CHUV), Lausanne, Switzerland, 5Rheumatology and Clin Immunol, Bern, Switzerland, 6Clinic for Rheumatology and Clinical Immunology, University Medical Center Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany, 7Department of Rheumatology, Immunology, and Allergology, Inselspital, University Hospital Bern, Bern, Switzerland

    Background/Purpose: Elevated levels of C-reactive protein (CRP) in systemic sclerosis (SSc) have been linked to early inflammatory stages of the disease. This study has been…
  • Abstract Number: 1728 • 2018 ACR/ARHP Annual Meeting

    Pharmacokinetics of Cyclophosphamide in Scleroderma Treated By Cyclophosphamide Versus Transplantation

    David Adams1, Keith Sullivan2, Ivan Spasojevic1, Ping Fan1, Mario Sampson3, Michael Cohen-Wolkowiez3, E. William St Clair4, Rob Woolson5, Jan Storek6, Mary Ellen Csuka7, Ashley Pinckney5, Beverly Welch8, Ellen Goldmuntz9, Daniel E. Furst10, Leslie Crofford11, Lynette Keyes-Elstein12, Maureen Mayes13, Peter McSweeney14 and Richard Nash14, 1Medicine, Duke University Medical Center, Durham, NC, 2Duke University Medical Center, Durham, NC, 3Pediatrics-Infectious Disease, Duke University Medical Center, Durham, NC, 4Rheumatology, Duke University Medical Center, Durham, NC, 5Rho Federal Systems, Inc., Chapel Hill, NC, 6University of Calgary, Calgary, AB, Canada, 7Medicine, Medical College of Wisconsin, Milwaukee, WI, 8National Institutes of Health, Bethesda, MD, 9NIAID, NIH, Bethesda, MD, 10University of Washington, Seattle, WA, 11Division of Rheumatology and Immunology, Vanderbilt University Medical Center, Nashville, TN, 12Clinical Statistics, Rho Federal Systems, Inc., Chapel Hill, NC, 13Rheumatology, University of Texas at Houston, Houston, TX, 14Colorado Blood Cancer Institute, Denver, CO

    Background/Purpose: The pharmacokinetics (PK) of cyclophosphamide (CP) and its primary active metabolite, 4-hydroxycyclophosphamide (4-OH-CP) have not been adequately studied in scleroderma. The hypothesis of this…
  • Abstract Number: 1820 • 2018 ACR/ARHP Annual Meeting

    Myeloablative Autologous Hematopoietic Stem Cell Transplantation for Severe Scleroderma: Long-Term Outcomes 6-11 Years after Entry on a Randomized Study Comparing Transplantation and Cyclophosphamide

    Keith Sullivan1, Ashley Pinckney2, Ellen Goldmuntz3, Beverly Welch4, Dinesh Khanna5, Robert W. Simms6, Suzanne Kafaja7, George Georges8, Jan Storek9, Mary Ellen Csuka10, Richard Nash11, Daniel E. Furst12, Leslie Crofford13, Peter McSweeney11, Maureen D. Mayes14 and Lynette Keyes-Elstein15, 1Duke University Medical Center, Durham, NC, 2Rho Federal Systems, Inc., Chapel Hill, NC, 3NIAID, NIH, Bethesda, MD, 4National Institutes of Health, Bethesda, MD, 5Division of Rheumatology, Department of Internal Medicine, University of Michigan Scleroderma Program, University of Michigan, Ann Arbor, MI, 6Rheumatology, Boston University School of Medicine, Boston, MA, 7David Geffen School of Medicine, UCLA, Los Angeles, CA, 8Clinical Research, Fred Hutchinson Cancer Research Center, Seattle, WA, 9University of Calgary, Calgary, AB, Canada, 10Medicine, Medical College of Wisconsin, Milwaukee, WI, 11Colorado Blood Cancer Institute, Denver, CO, 12University of Washington, Seattle, WA, 13Division of Rheumatology and Immunology, Vanderbilt University Medical Center, Nashville, TN, 14Rheumatology, University of Texas McGovern Medical School, Houston, TX, 15Clinical Statistics, Rho Federal Systems, Inc., Chapel Hill, NC

    Background/Purpose: The Scleroderma: Cyclophosphamide or Transplantation (SCOT) trial demonstrated that for adults with severe scleroderma (ACR 1995 criteria) and internal organ involvement, myeloablative CD34+selected autologous…
  • Abstract Number: 2647 • 2018 ACR/ARHP Annual Meeting

    Comparison of Low-Dose Intravenous Cyclophosphamide with Oral Mycophenolate Mofetil in the Treatment of Lupus Nephritis: Long Term Follow-up Data

    Manish Rathi1, Aman Sharma2, Joyita Sharma3 and Krishan L Gupta3, 1Department of Nephrology,, Postgraduate Institute of Medical Education and Research, Chandigarh, India, 2Clinical Immunology and Rheumatology Services, Department of Internal Medicine, Postgraduate Institute of Medical Education and Research, Chandigarh, India, Chandigarh, India, 3Nephrology, Post Graduate Institute of Medical Education and Research, Chandigarrh, India

    Background/Purpose: We present the long-term follow-up of patients with lupus nephritis who completed the randomized controlled trial on comparison of low-dose intravenous cyclophosphamide (IV CYC)…
  • Abstract Number: 2693 • 2018 ACR/ARHP Annual Meeting

    What Is the Effect of Cyclophosphamide Iv Pulse Therapy in Patients with Diffuse Cutaneous Systemic Sclerosis on Skin Involvement: An Observational Study

    Brigit Kersten, Nathan den Broeder, Frank van den Hoogen, Els van den Ende and Madelon Vonk, Rheumatology, Radboud University Medical Center, Nijmegen, Netherlands

    Background/Purpose: Patients with systemic sclerosis who have proximal skin involvement are classified as diffuse cutaneous systemic sclerosis (DcSSc). Patients with progressive skin involvement have worse prognosis.…
  • Abstract Number: 2742 • 2018 ACR/ARHP Annual Meeting

    Rituximab Versus Cyclophosphamide for Vasculitic Neuropathy: A Patient Reported Outcomes Study

    Aditi Patel1, Kevin Byram2, Yuxuan Jin3, Alexander Wu1, Yuebing Li4, Leonard H. Calabrese5 and Rula A Hajj-Ali6, 1Internal Medicine, Cleveland Clinic, Cleveland, OH, 2Cleveland Clinic Foundation, Cleveland, OH, 3Quantitative Health Sciences, Cleveland Clinic, Cleveland, OH, 4Department of Neurology, Cleveland Clinic, Cleveland, OH, 5Rheumatic & Immunologic Dis, Cleveland Clinic, Cleveland, OH, 6Rheumatic and Immunologic Disease, Cleveland Clinic Foundation, Cleveland, OH

    Background/Purpose: Vasculitic neuropathy (VN) is a major complication of systemic vasculitis and contributes to morbidity, functional limitation, and health care utilization in affected patients. Patient…
  • Abstract Number: 749 • 2017 ACR/ARHP Annual Meeting

    Treatment with Cyclophosphamide for Systemic Sclerosis-Interstitial Lung Disease Does Not Lead to a Sustained Improvement in Lung Function in Two Independent Cohorts

    Elizabeth R. Volkmann1, Donald P. Tashkin1, Myung Sim1, Ning Li2, Dinesh Khanna3, Michael Roth4, Philip J. Clements4, Anna-Maria Hoffmann-Vold5, Daniel E. Furst1, Grace Kim6, Jonathan Goldin1 and Robert Elashoff7, 1University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA, 2Biomathematics, University of California, Los Angeles, Los Angeles, CA, 3University of Michigan, Ann Arbor, MI, 4Medicine, University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA, 5Oslo University Hospital, Oslo, Norway, 6Radiology, University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA, 7University of California, Los Angeles, Los Angeles, CA

    Background/Purpose: Compared with placebo, treatment with cyclophosphamide (CYC) improved lung function in patients with systemic sclerosis-related interstitial lung disease (SSc-ILD) after 1 year in Scleroderma…
  • Abstract Number: 1684 • 2017 ACR/ARHP Annual Meeting

    Effectiveness and Safety of Tacrolimus Following Intravenous Cyclophosphamide Pulse Therapy As the Treatment of Systemic Sclerosis-Associated Interstitial Lung Disease

    Yuki Ichimura, Yasushi Kawaguchi, Kae Takagi, Akiko Tochimoto, Tomoaki Higuchi, Yasuhiro Katsumata and Hisashi Yamanaka, Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan

    Background/Purpose: Systemic sclerosis (SSc) is the disease characterized by organ fibrosis with unknown etiology, and pulmonary involvement is one of major cause of death. However,…
  • Abstract Number: 2603 • 2017 ACR/ARHP Annual Meeting

    Induction of Lupus Nephritisin in Real Situation: Cyclophosphamide or Mycophenolate Mofetil?

    Gabriela Munhoz1, Maira Lacerda1, Michelle Lopes1, Eduardo Ferreira Borba1, Luciana Seguro2 and Eloisa Bonfa3, 1Rheumatology, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, 2Rheumatology Division, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, 3Rheumatology Divison, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil

    Background/Purpose: Low-dose intravenous cyclophosphamide (Euro-lupus) and Mycophenolate mofetil (MMF) are well established in lupus nephritis induction therapy, but there are few studies comparing both treatments.…
  • 1
  • 2
  • 3
  • 4
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2023 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences